2024-07-29 04:00:16
“Are you coming for the paracetamol? » In the taxi leaving Agen station, this Friday, May 31, Said is inexhaustible about the star drug of French pharmacy. No need for GPS, the driver knows about one on the road that leads to the UPSA laboratory, installed since 1971 in a nearby town, about ten minutes from the city center of the capital- prune city On the bridge over the Garonne, here he launched into a powerful plea for medicine made in France. “There are more and more shortages in pharmacies, especially for treatment like paracetamol. If nothing is done, soon we won’t be able to take care of ourselves! », he exclaims, behind his wheel.
Paracetamol, the star analgesic drug in family medicine cabinets and first aid kits, is a form of fever reactions. It must be said that France swallows incredible amounts every year. “By 2023, more than 538 million paracetamol containers, either with a prescription or without a prescription, will have been distributed in French pharmacies. It is the most sold drug by volume in France »Notes David Syr, deputy general director of the Association for the development and production of statistics, an entity created by drug manufacturers to monitor pharmaceutical product data.
All syndromes combined, antidepressants, in all their brands and dosages, represent almost 19% of the prescriptions reimbursed by Health Insurance in 2023, not counting the consumption in the hospital . Of the ten most common prescriptions, eight are paracetamol, with Doliprane 1 gram tablets (173 million boxes sold in 2023) in first place. A star situation which, paradoxically, did not stop Sanofi, the owner of Doliprane, to announce its intention to part with this prototype drug.
1.1 billion euros
Headache, flu, toothache, body pain, periods of pain, fever, osteoarthritis flare-ups … The daily dose of mild and medium pains of paracetamol, introduced on the French market in the mid-1960s, helps to treat , has made it a timeless foundation.
In 2023, the consumer will represent around 1.1 billion euros in turnover, according to data from market expert Iqvia. “Sales depend on peaks in winter patterns, so there are differences from one year to another”explained Antoine Collet, director at Iqvia France, who noted the dominance in this market of two players, Opella, the consumer health subsidiary of Sanofi, and UPSA, which produces Efferalgan and Dabalgan. Only two pharmaceutical companies account for more than 93% of sales by value, with Sanofi taking the largest share of the pie, with almost 71% of the market.
You have 67.54% of this article left to read. The rest is reserved for subscribers.
#Paracetamol #France #sovereign #word